Regenerative Medical Technology Group Inc. (RMTG) — SEC Filings
Regenerative Medical Technology Group Inc. (RMTG) — 12 SEC filings. Latest: 10-Q (Nov 19, 2025). Includes 6 10-Q, 3 8-K, 2 10-K.
View Regenerative Medical Technology Group Inc. on SEC EDGAR
Overview
Regenerative Medical Technology Group Inc. (RMTG) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 19, 2025: Regenerative Medical Technology Group Inc. (RMTG) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $(6,419,566) compared to $(4,924,785) for the same period in 2024. This 30.35% increase in net loss was primarily driven by a substantial rise in inter
Sentiment Summary
Across 12 filings, the sentiment breakdown is: 1 bearish, 11 neutral. The dominant filing sentiment for Regenerative Medical Technology Group Inc. is neutral.
Filing Type Overview
Regenerative Medical Technology Group Inc. (RMTG) has filed 6 10-Q, 3 8-K, 2 10-K, 1 S-1 with the SEC between Jan 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (12)
| Date | Form | Description | Risk |
|---|---|---|---|
| Nov 19, 2025 | 10-Q | RMTG's Net Loss Widens 30% on Soaring Interest Costs | high |
| Aug 19, 2025 | 10-Q | Regenerative Medical Technology Group Inc. Files Q2 2025 10-Q | low |
| May 21, 2025 | 8-K | Regenerative Medical Technology Group Files 8-K | low |
| May 20, 2025 | 10-Q | Regenerative Medical Technology Group Files Q1 2025 10-Q | low |
| Apr 15, 2025 | 10-K | Regenerative Medical Tech Files 2024 10-K | low |
| Nov 19, 2024 | 10-Q | Regenerative Medical Tech Files Q3 2024 10-Q | medium |
| Oct 24, 2024 | 8-K | Meso Numismatics Files 8-K Report | low |
| Aug 14, 2024 | 10-Q | Meso Numismatics Files Q2 2024 10-Q | low |
| May 23, 2024 | 8-K | Meso Numismatics Files 8-K on Financials | low |
| May 20, 2024 | 10-Q | Meso Numismatics Files Q1 2024 10-Q | low |
| Apr 15, 2024 | 10-K | Meso Numismatics, Inc. Files 2023 Annual Report (10-K) | low |
| Jan 2, 2024 | S-1 | Meso Numismatics, Inc. Files S-1 Registration Statement | low |
Risk Profile
Risk Assessment: Of RMTG's 12 recent filings, 1 were flagged as high-risk, 1 as medium-risk, and 10 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $3.53M |
| Net Income | -$6.42M |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $1.19M |
| Operating Margin | N/A |
| Total Assets | $4.52M |
| Total Debt | $34.57M |
Key Executives
- Melvin Pereira
- Scott Doney, Esq.
Industry Context
The regenerative medical technology sector is characterized by high research and development costs, long product development cycles, and significant regulatory hurdles. Companies in this space often rely on substantial funding to advance novel therapies and technologies. The competitive landscape includes established pharmaceutical companies and numerous emerging biotech firms, all vying for market share and investor capital.
Top Tags
10-Q (6) · quarterly-report (5) · SEC Filing (3) · 8-K (2) · company-update (2) · 10-K (2) · retail (2) · Meso Numismatics (2) · Regenerative Medicine (1) · Biotechnology (1)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss | $6.42M | Increased from $4.92M in 2024 for the nine months ended September 30, 2025, a 30.35% increase. |
| Interest Expense | $5.44M | Increased from $4.62M in 2024 for the nine months ended September 30, 2025, a 17.75% increase. |
| Revenue | $3.53M | Increased from $2.60M in 2024 for the nine months ended September 30, 2025, a 35.86% increase. |
| Accumulated Deficit | $73.97M | Increased from $67.55M at December 31, 2024, indicating ongoing losses. |
| Total Liabilities | $34.57M | Increased from $31.18M at December 31, 2024, highlighting significant debt burden. |
| Long-term Notes Payable | $16.94M | Increased substantially from $2.00M at December 31, 2024, indicating a shift in debt structure. |
| Cash Used in Operating Activities | $(744,715) | A significant outflow compared to $471,306 cash provided in 2024, indicating operational cash burn. |
| Cash and Cash Equivalents | $1.19M | Slight increase from $1.17M at December 31, 2024, despite operational cash burn, likely due to new debt. |
| Loss on Extinguishment of Debt | $416,155 | A new expense in 2025, contributing to the increased net loss. |
| Common Shares Outstanding | 12,538,968 | Remained stable for the nine months ended September 30, 2025, compared to 2024. |
| Fiscal Year End | 2024 | The report covers the financial performance up to December 31, 2024. |
| Filing Date | 2025-04-15 | The 10-K was officially filed with the SEC on this date. |
| SEC File Number | 000-56010 | This unique identifier is assigned to the company's filings. |
| Fiscal Year End Date | December 31 | Annual Report period |
| Commission File Number | 000-56010 | SEC Filing identifier |
Frequently Asked Questions
What are the latest SEC filings for Regenerative Medical Technology Group Inc. (RMTG)?
Regenerative Medical Technology Group Inc. has 12 recent SEC filings from Jan 2024 to Nov 2025, including 6 10-Q, 3 8-K, 2 10-K. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of RMTG filings?
Across 12 filings, the sentiment breakdown is: 1 bearish, 11 neutral. The dominant sentiment is neutral.
Where can I find Regenerative Medical Technology Group Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Regenerative Medical Technology Group Inc. (RMTG) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Regenerative Medical Technology Group Inc.?
Key financial highlights from Regenerative Medical Technology Group Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for RMTG?
The investment thesis for RMTG includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Regenerative Medical Technology Group Inc.?
Key executives identified across Regenerative Medical Technology Group Inc.'s filings include Melvin Pereira, Scott Doney, Esq..
What are the main risk factors for Regenerative Medical Technology Group Inc. stock?
Of RMTG's 12 assessed filings, 1 were flagged high-risk, 1 medium-risk, and 10 low-risk.
What are recent predictions and forward guidance from Regenerative Medical Technology Group Inc.?
Forward guidance and predictions for Regenerative Medical Technology Group Inc. are extracted from SEC filings as they are enriched.